A BRIGHTE New Option: Fostemsavir for Drug Resistant HIV
| Overview / Abstract: |
Combination antiretroviral therapy has changed the trajectory of outcomes for people living with HIV by dramatically reducing morbidity and mortality from the virus. While first line therapeutic options are effective disease management strategies for most patients, treatment options are quite limited for those who have developed multidrug resistant HIV. This application-based continuing pharmacy education activity will provide a ‘journal club format’ discussion for pharmacists and student pharmacists to review the findings of the BRIGHTE study recently published in the New England Journal of Medicine. Join us to discuss the phase 3 clinical study evaluating the performance of the novel agent fostemsavir in patients with multidrug resistant HIV. |
|
Expiration |
Jun 10, 2023 |
|
Discipline(s) |
Pharmacy CPE |
|
Format |
Online, Webinar / Webcast / Video |
|
Cost |
$9.00 |
|
Credits / Hours |
0.10 |
|
Accreditation |
ACPE |
|
Presenters / Authors / Faculty |
John Zeuli, PharmD, BCPS-AQ ID, AAHIVP |
|
Keywords / Search Terms |
CEI Impact live, human immunodeficiency virus, litl, l2l, login to learn, log-in to learn, journal club, hiv, hiv therapy, brighte, fostemsavir, foste, bright, drug resistant, drug resistant hiv, drug-resist, drug resist, clinical trial, multidrug, multi-drug, multidrug-resistant hiv, multidrug-resistant, antiretroviral, antiretroviral therapy, hvi, antiretroviral agents |
|